TEVA PHARMACEUTICAL INDUSTRIES LTD

Drug pipeline (656)

Asset	Stage	Revenue	Trials	Status
ABACAVIR SULFATE AND LAMIVUDINE	approved	—	67	approved
ACARBOSE	approved	—	0	—
ACETAMINOPHEN AND CODEINE PHOSPHATE	approved	—	78	approved
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE	approved	—	78	approved
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE	approved	—	80	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (407)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01260922	phase1	completed	2006-04-01	2006-05-01	Teva Pharmaceuticals USA	10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.
NCT01260948	phase1	completed	2006-04-01	2006-05-01	Teva Pharmaceuticals USA	10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions
NCT00835575	phase1	completed	2003-07-01	2003-08-01	Teva Pharmaceuticals USA	15 mg Mirtazapine Orally Disintegrating Tablets, Fasting
NCT00834197	phase1	completed	2003-07-01	2003-08-01	Teva Pharmaceuticals USA	15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
NCT00835497	phase1	completed	2004-06-01	2004-06-01	Teva Pharmaceuticals USA	5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

FDA applications (2561)

Application

Approved

Type

Applicant

Products

ANDA 209813

2026-08-17

ANDA

TEVA PHARMACEUTICALS USA INC

ANDA 208757

2026-08-07

ANDA

ACTAVIS LABORATORIES UT INC

ANDA 214126

2026-07-28

ANDA

TEVA PHARMACEUTICALS USA INC

ANDA 216933

2026-07-21

ANDA

TEVA PHARMACEUTICALS INC

ANDA 209938

2026-07-13

ANDA

TEVA PHARMACEUTICALS USA INC